Dilution is one of the most frequently recurring events in the world of clinical-stage biotech investing, and one of the most misunderstood by retail investors encountering it for the first time. When a biotech company raises capital by issuing new shares, the total share count increases — which means each existing shareholder now owns a smaller percentage of the company than they did before. Understanding what dilution is, how biotech companies raise capital, when dilution is likely, and how to evaluate whether a specific raise is reasonable or destructive is foundational knowledge for any retail investor in the sector.
The Short Answer
| Dilution occurs when a company issues new shares, increasing the total share count and reducing each existing shareholder’s ownership percentage proportionally. For a pre-revenue clinical-stage biotech company, dilution is not a rare or exceptional event — it is a recurring feature of the business model. Most clinical-stage biotechs must raise capital multiple times before their drug reaches approval and generates revenue, and almost every capital raise involves issuing new shares. |
Why Biotech Companies Dilute So Often
Unlike companies in most industries, clinical-stage biotech companies have no revenue. They spend — often tens or hundreds of millions of dollars per year — on clinical trials, manufacturing, regulatory affairs, and personnel, while generating no offsetting income. The capital to fund this spending comes from investors, and the primary mechanism for raising that capital is issuing new shares.
This creates a structural cycle that every biotech investor must understand: the company raises capital to fund a clinical trial. The trial takes 18-36 months. If successful, the company raises more capital to fund the Phase 3 study. If Phase 3 succeeds, the company may raise again to fund the commercial launch. At every step, new shares are issued, diluting existing shareholders. The hope is that the drug’s ultimate value — as a commercial product or acquisition target — grows faster than the share count, so that the per-share value increases despite dilution.
Types of Dilutive Capital Raises
A follow-on public offering — also called a secondary offering — is the most common dilutive event. The company files a prospectus with the SEC and sells a defined number of new shares to institutional investors at a negotiated price, typically at a discount to the previous day’s closing price. The discount compensates buyers for the price impact and execution risk of the transaction. Follow-on offerings are typically announced pre-market and often cause an immediate drop in the stock price as the market adjusts for the new share count.
An at-the-market (ATM) offering is a facility that allows the company to sell shares gradually into the open market over time at prevailing market prices, through a registered agent. ATM programs are less immediately disruptive than a follow-on — there is no single announcement, no block discount — but the gradual share issuance creates constant low-level dilution. Many biotech companies establish ATM programs as a standing facility and draw on them opportunistically.
Convertible notes are debt instruments that convert into equity at a specific price upon a triggering event, such as a future equity offering. They are often structured with warrants — rights to purchase additional shares at a fixed price in the future. Warrants create what is called overhang: the potential for additional dilution if the stock rises above the warrant exercise price.
How to Evaluate a Capital Raise
Not all dilution is equal. The key variables in evaluating a capital raise are: the amount raised relative to the existing market cap, the price at which shares were issued relative to current trading, the resulting cash runway extension, and whether the capital raised is sufficient to fund the company to a meaningful value-creating milestone.
A raise that funds the company through its pivotal Phase 3 readout — removing the cash risk from the most important upcoming catalyst — is structurally different from a raise that provides only six months of additional runway and will likely require another raise before any value-creating milestone is reached. The former is the kind of dilution that experienced biotech investors can accept; the latter is a warning sign.
Non-Dilutive Alternatives
Not all biotech financing is dilutive. Non-dilutive funding sources include government grants (NIH, BARDA, DARPA), foundation grants, Orphan Drug tax credits, licensing deal upfront payments, and research collaboration payments from pharmaceutical partners. For small companies in rare disease or national security-relevant therapeutic areas, non-dilutive funding can constitute a meaningful portion of their operating capital and is highly valued precisely because it does not reduce existing shareholders’ ownership.
What This Does Not Guarantee
| The fact that a company has successfully raised capital does not validate its science or guarantee its drug will succeed. Capital raises reflect investor appetite and market conditions as much as the quality of the pipeline. A company that raises capital at a premium to book value in a strong biotech market may have the same clinical risk profile as a company that struggles to raise at a steep discount in a weak market. Evaluate the company’s clinical data independently of its fundraising history. |
Key Takeaways
- Dilution occurs when new shares are issued, reducing each existing shareholder’s ownership percentage — it is a recurring feature of pre-revenue biotech investing, not an exceptional event
- Common dilutive mechanisms include follow-on public offerings, at-the-market (ATM) programs, private placements, and convertible notes with warrants
- Follow-on offerings are typically priced at a discount to the prior day’s close and announced pre-market, causing an immediate stock price adjustment
- ATM programs allow gradual share issuance at market prices, creating constant low-level dilution without a discrete announcement event
- Warrants create dilution overhang — the potential for additional share issuance if the stock rises above the exercise price
- Evaluate a raise by how much runway it creates and whether it funds the company to a meaningful milestone, not just by the size of the discount
- Non-dilutive funding — grants, licensing deal upfronts, tax credits — is valued precisely because it funds operations without reducing shareholder ownership
Sources
1. SEC EDGAR — Prospectus filings (S-3, 424B4): https://www.sec.gov/cgi-bin/browse-edgar
2. SEC — Follow-On Offerings: https://www.sec.gov/investor/pubs/ipo.htm
3. NIH Grants: https://grants.nih.gov
4. FDA — Orphan Drug Tax Credit: https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.For full terms, see our Disclaimer.
